Three percent 5-ethyl-2'-deoxyuridine (EdU) in an aqueous cream base was compared with 5% acyclovir (ACV) in polyethylene glycol ointment and 3% EdU in 95% dimethyl sulfoxide (DMSO) for efficacy in the topical treatment of an experimental dorsal cutaneous herpes simplex virus type 1 infection in guinea pigs. Topical ACV treatment reduced the mean lesion number by 15%, the lesion area by 32%, and the lesion virus titer by 60% when compared with measurements at contralateral sites treated with the vehicle alone. Application of 3% EdU cream was more beneficial, effecting reductions of 29, 44, and 68% in the same measurements. EdU in DMSO was even more effective, reducing the lesion measurements by 39, 60, and 90%, respectively. The penetration of EdU and ACV through guinea pig skin was compared in single-chamber diffusion cells. In the aqueous cream, EdU readily penetrated excised skin and exhibited rates of flux 10-fold greater than those shown by ACV in ointment formnulation (0.56 versus 0.05 pg/cm2 per h; P = 0.05). The flux of EdU in DMSO was 3.39 jig/cm2 per h, six times higher than the flux in the cream vehicle. EdU was more effective than ACV in this experimental animal model, most likely due to better percutaneous drug delivery of EdU from the cream and DMSO vehicles.
The activity of 5-ethyl-2'-deoxyuridine (EdU) against infection with herpes simplex virus (HSV) was first recognized in 1967 (13) . In vitro testing by reduction in cytopathic effect has identified the mean 50% inhibitory dose against HSV type 1 (HSV-1) and HSV type 2 (HSV-2) to be 0.3 to 0.5 FLg/ml in primary rabbit kidney cells (8) and BHK-21 cells (22) . In vivo, EdU has shown efficacy in the rabbit model of HSV keratitis (17) and has been used in Europe for human herpes keratitis (11) . EdU was similar in efficacy to vidarabine parenterally in the treatment of HSV encephalitis in mice (7) and topically in the cutaneous HSV infection model in athymic nude mice (10) . In both athymic mice and guinea pigs, however, topical acyclovir (ACV) was more effective than EdU (5, 10) .
In the studies reported here, we examined the therapeutic efficacy of 3% EdU cream applied topically to the dorsal skin of guinea pigs infected with HSV-1 and the penetration of EdU through guinea pig skin in vitro. The results attained with EdU cream were compared with those for 5% ACV ointment and 3% EdU in 95% dimethyl sulfoxide (DMSO) tested concurrently.
( lished by thin-layer chromatography on a cellulose plate with an n-propanol-ammonium hydroxide-water (60:30:10) liquid phase (9) .
[3H]ACV (5%) in PEG was formulated by melting PEG at 40°C; recrystallized [3H]ACV was added to 5% by weight, and the mixture was then blended thoroughly at room temperature until the PEG base had resumed semisolid characteristics.
Experimental virus strain. The virus used was a stock of HSV-1 E115 that had a titer of 5 to 10 PFU/ml on Vero cells (20) . The concentrations of EDU and ACV that inhibited HSV-1 E115 plaque formation by 50% in Vero cells were 0.49 and 0.14 ,ug/ml, respectively.
Experimental animals. Hartley strain outbred female albino guinea pigs weighing 200 to 250 g each were obtained from Charles River Breeding Laboratories, Inc., Wilmington, Mass. During treatment, animals were housed in individual cages.
Animal inoculation and treatment. Guinea pigs were inoculated with HSV-1 E115 in six different areas on the depilated dorsum by multiple shallow punctures as originally described by Hubler (15) . This procedure regularly produces 30 to 50 pustules at each infection site when care is taken not to overlap the punctures (20) . Treatments were begun 24 h after inoculation at 0900 and were repeated at 0900, 1300, 1700, and 2100 h each day for a total of 3 days. Approximately 200 10-fold faster than ACV. The ability of EdU to penetrate skin from the cream formulation may explain its greater activity in the animal model, since EdU has less virus-inhibitory activity in vitro than ACV. When the penetration of EdU was further enhanced with DMSO, the therapeutic benefit in the animal model was twosfold greater than that of ACV ointment (60% versus 32%; P = 0.003).
In the present diffusion experiments, experimental conditions different from prior studies (19, 20) were used to examine whether circumstances more closely approximating in vivo conditions would affect the rate of drug penetration. threefold greater at 37°C under ambient conditions than at 25°C with the skin chamber sealed. One reason for the increase is that drug flux is proportional to molecular diffusivity, which is determined in part by temperature (degrees Kelvin) (18) . Further, because of the low ambient humidity in Utah, evaporation of water from aqueous cream likely occurs with the chamber uncovered, increasing the effective concentration of EdU and creating a steeper gradient across the skin (20) . Interestingly, the rate of EdU penetration at 37°C appears to increase with time ( Fig. 1, open triangles) , consistent with the latter explanation. We conclude that formulations with volatile components such as EdU cream are most accurately evaluated in vitro at body temperature and amnbient humidity.
We found that ACV formulated in PEG penetrated guinea pig skin poorly. These results, determined with [3H]ACV, confirm the findings of a prior study (20) in which ACV was measured by high-pressure liquid chromatography. There is no evidence as yet that ACV is less soluble in the stratum corneum than are other nucleoside antiviral agents. However, in addition to our ACV data, there is considerable evidence that PEG is a poor topical vehicle for a variety of molecules when skin penetration is the criterion (2) (3) (4) . We have also observed that trifluorothymidine in PEG pen- The antiviral action of EdU is similar to that of ACV. EdU binds selectively to HSV thymidine kinase, is ineffective against thymidine kinase-negative mutants of HSV, and has a high therapeutic index when concentrations of drug necessary to affect cellular functions are compared with -the amounts required for virus inhibition (6, 8) . EdU triphosphate is an effective substrate for HSV-induced DNA polymerase, and the mechanism of the virus-inhibitory action of the drug may be competitive inhibition of viral DNA polymerase or incorporation of the nucleotide analog into viral DNA or both (16) .
Although topical treatment of recurrent cutaneous HSV disease has been discouraging, failure to combine early treatment with a penetration-enhancing formulation may well account for the limited benefits seen to date (20, 21 
